Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioAtlaBCAB -2.66%15 EBIT per Share is $-41.61 as of Mar. 2026. GuruFocus rates BCAB with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 1,172 Biotechnology companies, BioAtla ranks better than 65.96% on this metric.
BioAtla's EBIT per Share for the
three
months ended in Mar. 2026 was $-6.20.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-41.61.
During the past 3 years, the average EBIT per Share Growth Rate was 28.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 20.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BioAtla's EBIT per Share or its related term are showing as below:
BCAB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -28.8 Med: 8.7 Max: 28.7
Current: 28.7
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of BioAtla was 28.70% per year. The lowest was -28.80% per year. And the median was 8.70% per year.
BCAB's 3-Year EBIT Growth Rate is ranked better than 65.96% of 1172
companies
in the Biotechnology industry
Industry Median: 15.5
vs BCAB: 28.70
BioAtla's EBIT for the
three
months ended in Mar. 2026 was $-9.31 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BioAtla EBIT per Share Related Terms
BioAtla EBIT per Share Historical Data
* Premium members only.
The historical data trend for BioAtla's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioAtla (BCAB) has a EBIT per Share of $-41.61 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioAtla and its competitors. According to the industry distribution chart, BioAtla ranks #399 out of 1172 companies in the Biotechnology industry, placing it in the top 34%.
Is BioAtla's EBIT per Share too high?
BioAtla's current EBIT per Share is $-41.61. Based on the distribution chart, BioAtla ranks #399 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioAtla has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BioAtla's EBIT per Share compare to RNAZ and APVO?
According to the Biotechnology industry distribution chart, BioAtla ranks #399 out of 1172 companies for EBIT per Share. This puts BioAtla in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioAtla and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioAtla's current EBIT per Share is $-41.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioAtla stock overvalued right now?
BioAtla (BCAB) has a current EBIT per Share of $-41.61. The current EBIT per Share is $-41.61. BioAtla's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BioAtla (BCAB), the current EBIT per Share is $-41.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
15GF Score
Get the complete analysis for BCAB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCAB has been successfully added to your 
